
|Articles|April 30, 2003
Nomogram for BPH progression risk offers aid in clinical decision-making
Chicago-Data from nearly 5,000 participants in the phase III studiesof dutasteride (Avodart) have been used to develop a nomogram for predictingthe probability that an individual patient with BPH will develop acute urinaryretention or require surgical intervention within 2 years and how that riskmay be altered by initiating dutasteride therapy.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
3
Andrea B. Apolo, MD, discusses survival gains with EV/pembrolizumab in bladder cancer
4
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
5